期刊文献+

消癥丸治疗乳腺增生的药物经济学评价

Pharmacoeconomic Evaluation of Xiaozheng Pills in Treating Breast Hyperplasia
原文传递
导出
摘要 目的对消癥丸治疗乳腺增生进行药物经济学评价。方法检索中国期刊全文数据库、万方数据知识服务平台、中文期刊全文数据库、Cochrane Library、Medline等数据库,收集从2000年1月至2021年7月发表的关于消癥丸治疗乳腺增生的临床试验,治疗周期为2个月或8周。统计文献的治疗有效率,核算治疗成本,计算成本-效果比(CER)和增量成本-效果比(ICER)。结果本研究共纳入3篇文献,消癥丸治疗乳腺增生的有效率均高于对照组。计算ICER得到以下结果,消癥丸对比乳癖消胶囊在治疗乳腺增生方面增加单位有效率需要多花费37.58元;消癥丸对比安慰剂在治疗乳腺增生方面增加单位有效率需要多花费17.85元;消癥丸对比乳结康丸在治疗乳腺增生方面增加单位有效率需要多花费19.38元。结论消癥丸治疗乳腺增生的临床疗效较好,且安全性较高,对比对照药物疗效更优,更具经济效益。 Objective To analyze the pharmacoeconomics of Xiaozheng pills in the treatment of breast hyperplasia. Methods The clinical trials on the treatment of breast hyperplasia with a treatment period of 2 months or 8 weeks were collected from January 2000 to July 2021 by searching the China National Knowledge Infrastructure, Wanfang Data Knowledge Service Platform, Chinese Journal Full Text Database, Cochrane Library, Medlineand other databases, and calculated the cost-effectiveness ratio(CER) and incremental cost-effectiveness ratio(ICER) by counting the effectiveness of treatment in the literature and accounting for the cost of treatment. Results A total of 3 literatures were included in this study, and the results showed the effective rate of Xiaozheng pills in the treatment of breast hyperplasia was higher than that of control group. It cost 37.58 yuan more to increase the efficiency per unit in the treatment of breast hyperplasia with Xiaozheng pills than Rupixiao capsules. It cost 17.85 yuan more to increase the efficiency per unit in the treatment of breast hyperplasia with Xiaozheng pills than placebo.It cost 19.38 yuan more to increase the efficiency per unit in the treatment of breast hyperplasia with Xiaozheng pills than Rujiekang pills. Conclusion Xiaozheng pills has better clinical efficacy and higher safety in the treatment of breast hyperplasia. Compared with the control drugs, it has better curative effect and more economic benefits.
作者 张雅宣 王佳 张亚云 余金明 ZHANG Ya-Xuan;WANG Jia;ZHANG Ya-Yun;YU Jin-Ming(School of Public Health,Fudan University,Shanghai 200032,China;School of Pharmacy,Shandong University,Jinan 250100,China;School of Pharmacy,Nanjing University of Chinesemedicine,Nanjing 210023,China)
出处 《中国药物经济学》 2022年第9期49-52,共4页 China Journal of Pharmaceutical Economics
基金 上海市公共卫生体系建设三年行动计划学科人才建设项目(GWV-10.1-XK14)。
关键词 消癥丸 乳腺增生 药物经济学评价 Xiaozheng pills Breast hyperplasia Pharmacoeconomic evaluation
  • 相关文献

参考文献17

二级参考文献134

共引文献492

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部